Overview

Saxagliptin Triple Oral Therapy

Status:
Completed

Trial end date:
2011-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether the addition of saxagliptin to a patient's combination treatment of metformin and sulfonylurea for a 24 week period will provide better control of the patient's type 2 diabetes and will be well tolerated.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Bristol-Myers Squibb

Treatments:

Metformin
Saxagliptin